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Citrus junos Tanaka peel ameliorates
hepatic lipid accumulation in HepG2 cells
and in mice fed a high-cholesterol diet
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Abstract
Background: Citrus junos Tanaka (yuja), a yellow-coloured citrus fruit has traditionally been consumed in Korea,
Japan, and China and has been found effective in preventing certain diseases. However, the inhibitory effect of yuja
on hepatic lipid accumulation has not been clearly elucidated thus far.
Methods: The inhibitory effect of yuja on hepatic lipid accumulation was investigated in both cell culture and mouse
models. We investigated the inhibitory effect of ethanol extract of yuja peel (YE) using HepG2 cells. We next confirmed
the effect of YE in mice fed a high cholesterol diet. Animals were divided into 4 groups (n = 8): a normal diet group
(ND), a high-cholesterol diet group (HC), high-cholesterol diet plus 1% YE (YL), high-cholesterol diet plus 5% YE (YH).
Result: Seventy percent ethanolic extracts of yuja peel (YE) reduced oleic acid-induced hepatic lipid accumulation in
HepG2 cells. Treatment with YE at 100, 200 μg/mL up-regulated expression levels of cholesterol metabolism-related
proteins such as AMPK, ACC, PPAR-α, and CPT1 and down-regulated the expression of 3-hydroxy-3-methylglutaryl
coenzyme A reductase. The hypocholesterolemic effect of YE was further confirmed in mice fed a high-cholesterol diet.
Compared to ND (normal diet) mice, HC (high-cholesterol diet) mice showed increased body weight, liver fat content, liver
weight, and content of total cholesterol and low-density lipoprotein (LDL) cholesterol. On the contrary, administrations of
YL (HC + 1% YE) or YH (HC + 5% YE) significantly reduced body weight, liver fat content, liver weight, total cholesterol, and
LDL cholesterol compared to those of only HC fed mice group. As a result of in vitro data, protein expressions of PPAR-α
and CPT1 were induced in mice fed YE diet compared to HC diet but HMGCR expression was decreased.
Conclusions: Yuja peel ameliorates hepatic lipid accumulation in both cell culture and mouse models and therefore, could
serve as a useful supplement for hypercholesterolemia.
Keywords: Citrus junos Tanaka, Hepatic lipid accumulation, High cholesterol diet, HepG2 cell
Background
Lifestyle-related diseases including hepatic lipid accumula-
tion are associated with irregular lifestyle and diet. Hepatic
lipid accumulation is accompanied by excessive accumula-
tion of cholesterol and triglycerides, thereby causing athero-
sclerosis, which affects the lipid‐laden blood vessels, or
hepatic steatosis, or both. It is well established that low-
density lipoproteins (LDLs) play a central role in the devel-
opment of atherosclerosis. LDL promotes formation of fatty
streaks, a key event in early atherosclerosis and induces the
uptake of oxidized LDL by macrophages and smooth
muscle cells. A negative correlation has been demonstrated
between LDL and high-density lipoproteins (HDLs). High
level of HDL can inhibit LDL oxidation by various mecha-
nisms [1]. Several studies have shown that natural ingredi-
ents are effective in preventing hypercholesterolemia by
suppressing LDL oxidation [2]. For example, cocoa poly-
phenols inhibit LDL oxidation, thereby suppressing the
formation of atherosclerosis. The intake of dairy cocoa
powder was shown to reduce LDL oxidation in humans [2].
It was also reported that vitamin E supplementation in-
hibits LDL accumulation in arterial diseases. A clinical
study reported that almonds significantly reduced total
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cholesterol (range 8-12%) and LDL cholesterol (range 9–
15%) [3]. Therefore, reduction of total cholesterol and LDL
cholesterol levels may be a significant strategy for prevent-
ing atherosclerosis.
Another mechanism of preventing hypercholesterolemia
includes targeting enzymes including AMPK and 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR).
AMPK is a metabolic protein, which plays a central role in
lipid metabolism and inhibits anabolic pathways, including
cholesterol synthesis by targeting HMGCR [4]. HMGCR is
a rate-limiting enzyme in cholesterol synthesis pathway; it is
suppressed by cholesterol derived from the degradation of
LDL via the LDL receptor [5]. HMGCR is inhibited by
statins, which upregulate the expression of LDL receptors in
the liver, resulting in increased catabolism of plasma LDL
and decreased plasma cholesterol [5]. Thus, AMPK and
HMGCR enzymes are the targets of various cholesterol-
lowering natural ingredients.
Citrus junos Tanaka, also known as yuja is a yellow-
coloured citrus fruit that has been reported to exhibit
beneficial health effects against oxidative stress and
inflammation [6, 7]. In our previously paper, several ac-
tive compounds found in yuja exist as rutin, quercetin,
tangeretin, naringin and hesperidin [6]. In addition, our
studies have also reported the beneficial health effects of
yuja, such as potent antidiabetic, anticancer, and anti-
inflammatory effects, both in in vitro and in vivo [6, 7].
The present study investigated the effects of yuja on
hepatic lipid accumulation. A 70% ethanolic extract of
yuja peel was examined for its effects on oleic acid-
induced hepatic lipid accumulation, AMPK activation,
and HMGCR expression in HepG2 cells. Further, the
same ethanolic extract was evaluated in mice fed a high-
cholesterol diet, because mice fed high-cholesterol diet




bromide) and Oil Red O were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Triglyceride (TG), Total
Cholesterol (TC), Glutamic Oxaloacetic Transaminase
(GOT), Glutamic Pyruvic Transaminase (GPT), and
Alkaline Phosphatase (ALP) kits were purchased from Asan
Pharmaceutical company (Seoul, Republic of Korea). Fatty
Acid Synthase (FAS), Carnitine Palmitoyl Transferase-1
(CPT-1), and Peroxisome Proliferator-Activated Receptor-α
(PPAR-α) antibodies were purchased from santacruz
Biotechnology Inc. (Santa Cruz, CA, USA), 3-Hydroxy-3-
Methylglutaryl-Coenzyme A Reductase (HMGCR) was
purchased from Cell Signaling (Beverly, MA, USA). β-Actin
was purchased from Bethyl Laboratories (Montgomery,
TX, USA).
Preparation of Yuja extracts
Yuja was provided by Goheung Country Office (Goheung,
Republic of Korea), where a voucher specimen was depos-
ited. Yuja peel extracts (YE) were prepared as described
previously [7]. Briefly, yuja peels were dissolved in a 10-fold
volume of 70% ethanol by shaking for 24 h at 25 °C, and
precipitates were removed by centrifugation at 8000xg for
30 min. Supernatants were dried using freeze dryer. Yuja
extract was dissolved in DMSO and used to treat HepG2
cells and mice fed high fat diet. The cells were incubated
with 1% BSA-supplemented low-glucose DMEM (None),
0.5 mM oleic acid (OA) in 1% BSA-supplemented low-
glucose DMEM, and 0.5 mM OA in DMEM with 50, 100,
and 200 μg/mL YE as a treatment group for 24 h.
Cell culture and sample treatment
HepG2 cells were purchased from the American Type
Culture Collection (Mannassas, VA, USA). These cells
were grown in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and antibiotics, which were purchased from
Welgene Inc. (Daegu, Republic of Korea). The cells were
maintained at 37 °C in a humidified atmosphere under 5%
CO2. When processing the sample on the cells, cells were
treated with 1% BSA in low-glucose DMEM (None),
0.5 mM oleic acid (OA) in 1% BSA-supplemented low-
glucose DMEM, and 0.5 mM OA in DMEM with 50, 100,
and 200 μg/mL YE as a treatment group for 24 h.
Cytotoxicity (MTT assay)
HepG2 cells were cultured in 24-well plates and treated
with YE at the indicated concentrations. Then, 10 μL of
MTT solution (5 mg/mL in PBS) was added and incu-
bated for 3 h. After removing the medium, the cells were
dissolved in dimethylsulfoxide (DMSO), and 100 μL of
supernatant was transferred to 96-well plates. Absorb-
ance was measured at 540 nm using microplate reader
(Molecular Device Co., Sunnyvale, CA, USA).
Oil Red O staining
HepG2 cells were cultured in 24-well plates and then
treated with YE for 24 h. After treatment, they were stained
with Oil Red O to measure lipid droplet accumulation,
washed with 200 μL of PBS, and fixed with 200 μL of 4%
formaldehyde for 15 min, at room temperature (RT). The
cells were then washed three times with PBS, incubated
with 200 μL of 60% isopropanol for 5 min, and then stained
with 200 μL of 0.1% Oil Red O staining solution for 60 min
at RT. The cells were further washed 3 times with 1 mL of
water. The images of these cells were captured by micros-
copy (Olympus, Tokyo, Japan). To measure lipid accumula-
tion, the cells were dissolved in isopropanol for 10 min.
The dissolved dye was transferred to 96-well plates and the
absorbance was measured at 510 nm.
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Western blot assay
The proteins were harvested in RIPA buffer (Elpis, Daejeon,
Republic of Korea) containing a protease inhibitor and a
phosphatase inhibitor (Roche, Basel, Switzerland). After this
treatment, the protein was quantified using Bicinchoninic
Acid (BCA) methods. The protein samples (20 μg) were
loaded onto 10% Bis-Tris gel and transferred to nitrocellu-
lose membranes. The membrane was blocked using 5%
skim milk solution for 1 h and probed with each antibody
at 4 °C overnight. After triplicate washing with PBS, the
membrane was incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 h. It was washed
again with PBS and the protein expression was detected by
chemiluminescence methods.
Animal fed a high-cholesterol diet
Male C57BL/6 J mice (3 weeks old) were housed at the
Korea Food Research Institute (KFRI) in a climate-
controlled environment (24 °C at 50% relative humidity)
with a 12 h light/dark cycle. After 1 week of adaptation, the
mice were randomly divided into four groups (n = 8): N
(Normal diet), HC (high-cholesterol diet), YL (HC+ 1%
YE), and YH (HC+ 5% YE). D12336 diet (high-cholesterol
diet, Purified diet to match Paigen’s atherogenic rodent diet,
Research Diets, Inc.) was used as HC. The composition of
the high cholesterol diet was as follow: 46% carbohydrate,
16% fat, 21% protein, 12.5% cholesterol, 0.5% cholic acid,
mineral mixture and vitamin mixture (source of carbohy-
drate =maltodextrin, sucrose and corn starch; source of fat
= soybean oil, cocoa butter and coconut oil; source of
protein = casein, soy protein and DL-methionine, source of
mineral mixture = calcium carbonate, sodium chloride, po-
tassium citrate; vitamin mixture = choline bitartrate). The
mice were fed these diets for 10 weeks with free access to
autoclaved tap water in cages. The total daily intake and
weight of mice were recorded every week for up to
10 weeks. At the end of the experiment, animals were
sacrificed to collect their blood and liver tissue samples,
which were then stored at −70 °C. Our experimental proto-
col was approved by the Institutional Animal Care and Use
Committee of the Korea Food Research Institute.
Hematoxylin and eosin (H&E) staining
Liver tissues were fixed using 4% formaldehyde solution
and cut into 4-μm-thick portions, which were stained
with hematoxylin and eosin, and images were captured
using a microscope (Olympus, Tokyo, Japan).
Measurement of enzyme and lipid change in blood
The collected blood samples were centrifuged at 12000 rpm
for 15 min at 4 °C. After centrifugation, the serum was
transferred to a new centrifuge tube and then stored at
−70 °C. Blood serum levels of TG, TC, HDL-cholesterol,
GOT, GPT, and ALT were analysed according to the manu-
facturer’s protocol.
Statistical analysis
Results obtained from at least three independent in vitro
studies were expressed as mean ± standard deviation (SD).
The results were determined by nonparametric methods
using the SPSS computer-based statistics programs (Ver.
20; SPSS Inc., Chicago, IL, USA). In case of in vivo studies
using mice, the results are expressed as mean ± standard
error of mean (SE). Statistical differences between mean
values were evaluated by one-way analysis of variance
(ANOVA) followed by Bonferroni test. A P value of <0.05
was considered statistically significant.
Results
Inhibition of OA-induced hepatic lipid accumulation by
YE without toxicity in HepG2 cells
To determine the inhibitory effect of YE on hepatic lipid
accumulation, lipid accumulation was evaluated using Oil
red O staining of HepG2 cells. As shown in Fig. 1a and b,
treatment with 0.5 mM OA significantly induced lipid ac-
cumulation by about 16% compared to control (untreated
HepG2 cells). Co-treatment with 0.5 mM OA and YE (100,
200 and 400 μg/ml) significantly inhibited up to 23% OA-
induced lipid accumulation in a dose-dependent manner.
Under similar conditions, the effect of YE on cell viability
was also determined by MTT assay. There were no signifi-
cant differences in cell viability, indicating that the tested
concentrations of YE did not affect cell viability (Fig. 1c).
Similar results were obtained for treatment with only YE
(Fig. 1d). These results suggest that YE has preventive
effects against OA-induced hepatic lipid accumulation
without cell toxicity.
Prevention of hepatic lipid accumulation by YE via
modulation of AMPK signalling HMGCR, PPAR-α, and
CPT-1 in HepG2 cells
AMPK is a potential modulator of metabolism of lipid
accumulations via up-regulation of fatty acid oxidation
and down-regulation of lipogenesis, glucose production,
and protein synthesis [4]. In view of this information,
the effect of YE on AMPK signalling was investigated.
HepG2 cells were incubated with OA, as well with OA
and YE for 1 h. As shown in Fig. 2a, YE stimulated the
phosphorylation (Thr172) of AMPK and its major down-
stream targeting enzyme, ACC. These results indicated
that the AMPK signalling pathway is the potential target
of YE, thereby preventing hepatic lipid accumulation in
HepG2 cells. To investigate the specific downstream of
AMPK activation, the effects of YE on the expression of
lipid metabolism-related proteins were evaluated, such
as HMGCR, PPAR-α, and CPT1, which are known for
fatty acid β-oxidation [8, 9]. Treatment with OA alone
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did not affect HMGCR, PPAR-α, and CPT1 expression.
However, co-treatment with OA and YE reduced HMGCR
expression. In contrast, co-treatment with OA and YE
induced PPAR-α and CPT1 expression (Fig. 2b). These re-
sults indicated that YE inhibited OA-induced hepatic lipid
accumulation via AMPK signalling, in particular, by stimu-
lating PPAR-α and CPT1, β-oxidation-related proteins and
reducing HMGCR proteins involved in lipogenesis.
Inhibition of increases in body weight and liver weight by
YE in HC-fed mice
To further examine the hypocholesterolaemic effects of
YE, studies were carried out using HC-fed mice. High
cholesterol diet caused fatty liver in this mice model.
While the food intake in normal group is higher than in
HC group (Fig. 3b), As Fig. 3a, the body weight between
the normal and HC groups did not differ significantly
(28.4 ± 0.9 vs. 28.3 ± 0.7 g, normal vs. HC group). YL (HC
+ 1% YE) and YH (HC+ 5% YE) group mice had signifi-
cantly lower body weights than normal or HC group mice
(26.2 ± 0.3, 25.1 ± 0.4, respectively, vs. 28.3 ± 0.7 g, YL, YH
vs. HC group). In addition, YL and YH group showed
inhibited fat droplet accumulation compared with HC
group in the liver (Fig. 3c). And YL group mice showed
reduced liver weight compared to HC group mice (Fig. 3d).
These result suggested that administration of YE pro-
tected the mice from HC-induced fatty liver.
Attenuation of serum biomarkers increased HC by YE in mice
To examine the effects of YE on serum biomarker, the
serum levels of GPT, GOT, and ALP were evaluated. The
levels of GPT, GOT, and ALT, which are indicative of liver
activity, increased in the HC group. In contrast, the levels
of GPT, GOT and ALT significantly decreased in the YL
Fig. 1 Effects of 70% ethanolic extracts of yuja peel (YE) on hepatic lipid accumulation in and viability of HepG2 cells. HepG2cells were treated for
24 h with YE in the presence or absence of oleic acid (OA), and then lipid accumulation was measured by Oil-Red O staining (a, b). Cytotoxicity
was measured by the MTT assay (c, d). All results are expressed as the mean ± SD. *p < 0.05 vs. control (None); #p < 0.05 vs. OA
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and YH groups (Fig. 4a, b, c). Next, we analysed serum
cholesterol, HDL, and LDL levels. Along with hepatic lipid
accumulation, cholesterol and LDL levels of HC group
dramatically enhanced compared with normal diet group.
Supplementation with YL and YH attenuated the HC-
induced blood levels of TC and LDL, with little effect on
HDL cholesterol levels (Fig. 4d, e, f ). These results indi-
cated that YE exerts hypocholesterolaemic effects against
HC-induced lipid accumulation by improving the blood
lipid levels and liver activity.
Inhibition of FAS, HMGCR and induction of PPAR-α
hepatic protein expressions by YE in mice
We further examined protein expressions related to lipid
metabolism in liver tissue. Consistent with the vitro pro-
tein results in HepG2 cells, administration of HC with
YL and YH groups inhibited HMGCR and FAS protein
expressions compared to HC group (Fig. 5a, b, c). On
the other hands, only administration of YL increased ex-
pressions of PPARα which are involved in β-oxidation
(Fig. 5a, d), but not in YH groups.
Taken together, both in vitro and in vivo data showed
that YE attenuated hepatic lipid accumulation by multiple
mechanisms such as fatty acid oxidation, lipogenesis.
Discussion
In the present study, the hypocholesterolemic effect of YE
was evaluated in a cell culture system and in mice fed an
HC. It was also demonstrated that YE reduces hepatic
lipid accumulation, HMGCR expression, and induces the
phosphorylation of AMPK without cytotoxicity in HepG2
cells. Furthermore, 1% YE (YL) or 5% YE (YH) reduces
the body weight, liver fat content, liver weight, total chol-
esterol, and LDL cholesterol in mice fed an HC.
HepG2 cells have been proposed to be a valuable model
for screening of hypocholesterolemic agents [10]. To de-
termine the safety of plant extracts, a cytotoxicity assay
was performed before evaluating physiological activities in
vivo studies. Therefore, the cytotoxicity of YE in HepG2
cells was evaluated using the MTT assay. No significant
cytotoxicity was observed (Fig. 1). Treatment with YE was
also shown to reduce OA-stimulated hepatic lipid accu-
mulation in HepG2 cells. In addition, treatment with YE
induces protein expressions of AMPK, PPAR-α, CPT1
and inhibits HMGCR expression in OA-mediated HepG2
cells. Lovastatin and simvastin have been used as inhibi-
tors of HMGCR, a major target for cholesterol synthesis
[11]. HMGCR catalyses the conversion of HMG-CoA to
mevalonic acid, which is a rate-limiting step in cholesterol
biosynthesis [5, 11]. Therefore, YE may inhibit the conver-
sion of HMG-CoA to mevalonic acid by HMGCR without
any cytotoxicity. In addition, AMPK was phosphorylated
by YE in HepG2 cells. AMPK is an upstream regulator of
HMGCR and many investigators have focused on the role
of AMPK for the development hypocholesterolemic com-
pounds [4]. For example, several plant extracts and ingre-
dients have been reported to be effective in inhibiting
HMGCR and AMPK, such as caffeine, berberine, and
Artemisia scoparia extract [12–14]. This is in agreement
with our result that the hypocholesterolemic effect of YE
is modulated via the AMPK/HMGCR pathways.
Based on the above results from HepG2 cell culture, an
animal study was conducted using mice fed an HC. 1% YE
(YL) or 5% YE (YH) ameliorates hypercholesterolemia by
Fig. 2 Effects of 70% ethanolic extracts of yuja peel (YE) on AMPK signalling and expression of proteins associated with cholesterol metabolism.
HepG2cells were treated for 1 h with YE in the presence or absence of oleic acid, and then western blot analysis was performed with phospho-specific
ACC, AMPK, normal AMPK, and beta-actin antibodies (a). HepG2cells were treated for 24 h with YE in the presence or absence of oleic acid, followed
by western blot analysis with 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), peroxisome proliferator-activated receptor (PPAR)-α,
carnitine palmitoyltransferase (CPT)-1, and beta-actin antibodies (b)
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decreasing weight gain, liver fat content, liver weight, total
cholesterol, and LDL cholesterol content. Liver weight
and ALT values of YL groups was more effective than that
of YH group. On the other hand, the overall results of YH
groups were better than that of YL group. Several recent
studies demonstrated that consumption of plant extracts de-
creases the level of LDL, an important factor for cardiovas-
cular diseases. Increased level of cholesterol results in
atherosclerosis due to the increased lipid peroxidation [14–
16]. Thus, LDL peroxidation is an important target for the
prevention of atherosclerosis and can be prevented by anti-
oxidants. Owing to minimal side effects, natural products
are reported as an alternative for the prevention of athero-
sclerosis. Several plants have antioxidative properties. In pre-
vious studies, Biebersteinia multifida DC (Geraniaceae) was
shown to have an antioxidant effect and significantly de-
creased the level of LDL [17]. The antioxidant ability of this
plant possibly facilitates its hypocholesterolemic effect. Our
previous study has shown that yuja peel has antidiabetic ac-
tivity and has several phenolic compounds, including rutin,
quercetin, tangeretin, naringin, and hesperidin [6, 7]. Most
of these compounds have excellent anti-oxidant abilities.
Citrus flavonoids have been reported to have the hypocho-
lesterolemic effects [18]. Our previous study showed that
tangeretin could reduce the levels of circulating lipid me-
diators, including total cholesterol, in obese mice [19]. In
the present study, YE reduced weight gain, liver fat con-
tent, liver weight, total cholesterol, and LDL cholesterol
content in mice fed an HC. Besides, YE also inhibited
HMGCR, FAS and stimulated PPARα expressions in liver
Fig. 3 Effects of 70% ethanolic extracts of yuja peel (YE) on body weight and liver weight in high-cholesterol diet (HC)-fed mice. Experimental mice
were fed normal diet, HC, and HC supplemented with 1% (YL) or 5% (YH) YE for 10 weeks. Body weight (a), food intake (b), liver fat accumulation (c),
and liver weight (d) were measured, as described in materials and methods. Results are expressed as mean ± SE. *p < 0.05 vs. HC
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tissue compared to HC-fed groups like in vitro results.
These results indicate that YE have the potential to im-
prove hypercholesterolemia, which could be attributed to
the antioxidant effect of polyphenol compounds. These
compounds have an aromatic-ring structure with various
substitutions [20]. The 3-hydroxyl group on the aromatic
ring is a hydrogen donor and has an antioxidant effect
[20]. Therefore, it is speculated that the 3-hydroxyl group
of flavonoids that are abundant in YE is important for the
hypocholesterolemic effect.
Fig. 4 Effects of 70% ethanolic extracts of yuja peel (YE) on biochemical parameters related to cholesterol metabolism. Experimental mice were
fed normal diet, high-cholesterol-diet (HC), and HC supplemented with 1% (YL) or 5% (YH) YE for 10 weeks. Serum levels of (a); glutamic pyruvic
transaminase (GPT), (b); glutamic oxaloacetic transaminase (GOT), (c); alanine phosphatase (ALP-S), (d); total cholesterol (TC), (e); low-density
lipoprotein (LDL), (f); and high-density lipoprotein (HDL) were measured, as described in materials and methods. Results are expressed as
mean ± SE (n = 8). *p < 0.05 vs. ND; #p < 0.05 vs. HC
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Conclusions
In this study, we demonstrate the hypocholesterolemic
effect of 70% ethanolic extract of yuja peel in HepG2
cells. A 70% ethanolic extract of yuja peel also reduced
weight gain, liver fat content, liver weight, total choles-
terol, and LDL cholesterol content. Therefore Citrus
junos Tanaka (yuja) may be useful for preventing
atherosclerosis.
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